Shots:
The companies collaborated to advance TransCode’s pipeline of RNA-targeted oncology therapies and diagnostic products for the treatment of cancer
In order to broaden the use of TransCode’s discovery engine and to further validate the therapeutic & diagnostic candidates, TransCode & MD Anderson scientists will work together on preclinical research
The collaboration could influence numerous clinical programs in TransCode’s pipeline, beginning with TTX-MC138 for metastatic cancers. The P-0 trial is expected to be initiated for TTX-MC138 to deliver therapeutic candidate to metastatic lesions in patients with advanced solid tumors
Ref: TransCode Therapeutics | Image: TransCode Therapeutics
